Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat".
Los Angeles County-University of Southern California Medical Center.|Division of Infectious Diseases, University of Southern California Keck School of Medicine, Los Angeles.
Brad
B
Spellberg
Departments of Medicine, Pharmacology, and Molecular Biology and Microbiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Case Western Reserve University, Ohio.
Robert A
RA
Bonomo
D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D000073182:Carbapenem-Resistant Enterobacteriaceae; D002442:Ceftazidime; D004338:Drug Combinations; D004755:Enterobacteriaceae; D004756:Enterobacteriaceae Infections; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases
D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D002442:Ceftazidime; D001618:beta-Lactamases
CRE; Enterobacteriaceae; antibiotic resistance; carbapenem-resistance; ceftazidime-avibactam